All articles tagged: Abnormal weight loss (R63.4)

Tirzepatide is associated with significantly greater weight loss than semaglutide for adults with overweight or obesity, according to a study published online July 8 in JAMA Internal Medicine.Patricia J. Rodriguez, Ph.D., from Truveta Inc. in Bellevue, Washington, and colleagues compared on-treatment weight loss and rates of gastrointest

The annual meeting of the American Diabetes Association was held this year from June 21 to 24 in Orlando, Florida, drawing more than 15,000 participants from around the world, including clinicians, academicians, allied health professionals, and others interested in diabetes. The conference highlighted the latest advances in di

Metabolic surgery is associated with significantly lower risk of major adverse cardiovascular events (MACE) compared with nonsurgical management among patients with moderate-to-severe obstructive sleep apnea (OSA) and obesity, according to a study published online June 21 in the Journal of the American College of Cardiology.Ali Aminian,

For patients with obesity-related heart failure with preserved ejection fraction (HFpEF), semaglutide reduces body weight to a greater extent in women but yields similar improvements in heart failure-related symptoms in men and women, according to a study published online June 23 in the Journal of the American College of Cardiology to coinc

At-home, self-administered transcranial direct current stimulation (tDCS) and attention bias modification training (ABMT) is feasible, acceptable, and shows promising efficacy for treatment of binge eating, according to a study published online June 6 in BJPsych Open.Michaela Flynn, Ph.D., from King's College London, and colleague

Roux-en-Y gastric bypass (RYGB) is successful in achieving long-term sustained weight loss and diabetes remission, according to a study presented at the annual meeting of the American Society for Metabolic and Bariatric Surgery, held from June 9 to 13 in San Diego.John Nguyen-Lee, M.D., from the Geisinger Medical Center in Danville, Pennsylva

Combining antiobesity medications enhances preoperative weight loss in individuals with high body mass index (BMI) preparing for metabolic surgery, according to a study presented at the annual meeting of the American Society for Metabolic and Bariatric Surgery, held from June 9 to 13 in San Diego.Michael Kachmar, D.O., from the Pennington Biome

The article discusses a survey showing the rise in popularity of Ozempic, a GLP-1 drug, for type 2 diabetes. It highlights the drug's effectiveness and patient satisfaction, leading to increased prescriptions. However, concerns remain about its cost and accessibility for some patients.

Dr. Laure DeMattia, a bariatric medicine specialist, highlights the frustration faced by her patients as they struggle to access these medications despite exhausting other weight loss methods. Many patients, particularly those with Medicare and Medicaid, encounter difficulties in obtaining prescriptions for these drugs due to lack of coverage.

"Wegovy," an obesity drug, is approved for reducing heart attack and stroke risk. It's a higher-dose version of a diabetes medicine that aids weight loss. The drug's approval signals a new option for tackling obesity-related health risks.

Toby Keith, a beloved figure in the country music scene, has recently passed away, leaving fans and the music industry in mourning. However, his death has also brought attention to an important health issue: stomach cancer. In this article, we’ll delve into the details of stomach cancer, Toby Keith’s battle with the disease, and what can be learned from his experience.

Individuals with recent weight loss have a significantly increased risk for cancer during the subsequent 12 months, according to a study published online in the Jan. 23/30 issue of the Journal of the American Medical Association.Qiao-Li Wang, M.D., Ph.D., from Harvard Medical School in Boston, and colleagues examined the rates of subseq

Remission of type 2 diabetes is feasible and is associated with weight loss in the year after diabetes diagnosis, according to a study published online Jan. 23 in PLOS Medicine.Hongjiang Wu, from The Chinese University of Hong Kong, and colleagues examined the association of weight change at one year after diabetes diagnosis with long-

The CNN article examines changing views on body weight, discussing obesity's classification as a disease and the rise of effective weight loss medications. It addresses the societal and medical implications, including weight-related stigma and the limitations of BMI, while exploring new perspectives on obesity and health.

Use of the glucagon-like peptide 1 receptor (GLP-1R) agonist liraglutide exerts weight loss-independent, GLP-1R-dependent effects on insulin sensitivity, according to a study published online Oct. 24 in Diabetes.Mona Mashayekhi, M.D., Ph.D., from Vanderbilt University Medical Center in Nashville, Tennessee, and colleagues examined whet

In a preliminary review, the U.S. Food and Drug Administration says it has found no evidence drugs like Wegovy and Ozempic cause suicidal thoughts or actions.Still, the agency noted officials cannot rule out that "a small risk may exist," and it will continue to look into similar reports involving these glucagon-like peptide-1 receptor agonists.

Later-stage persistence with antiobesity medication (AOM) varies based on the drug and six-month weight loss, according to a study published online Dec. 6 in Obesity.Hamlet Gasoyan, Ph.D., M.P.H., from the Cleveland Clinic, and colleagues examined the percentage of patients with an initial AOM fill who were persistent with AOM at th

At least 251 cases of lead poisoning linked to tainted fruit puree pouches have now been reported in 34 states, U.S. health officials said.That's up from 205 cases reported in the last weekly tally, the U.S. Centers for Disease Control and Prevention noted in its&nbsp;<a href="https://www.cdc.gov/nceh/lead/news/lead-poisoning-outbreak-linked-

A low-fat vegan diet that includes soy may result in gut microbiome changes that are associated with a decrease in postmenopausal hot flashes, according to a study published in the December issue of&nbsp;Complementary Therapies in Medicine.Hana Kahleova, M.D., Ph.D., from the Physicians Committee for Responsible Medicine in Washington,

According to the latest University of Michigan National Poll on Healthy Aging, about three in four older Americans (76 percent) believe Medicare should cover the cost of weight-loss medications like Ozempic, Wegovy, or Zepbound.More than four out of five older adults (83 percent) think insurance companies should pay for drugs that help people

For individuals with overweight or obesity and knee or hip osteoarthritis (OA), a slow-to-moderate, but not a fast, rate of weight loss is associated with a reduced risk for all-cause mortality, according to a study published online Dec. 6 in Arthritis &amp; Rheumatology.Jie Wei, Ph.D., from Xiangya Hospital in Changsha, China, and col

Eli Lilly has announced that its newly approved weight-loss medication, Zepbound, is now available for patients to take."Today opens another chapter for adults living with obesity who have been looking for a new treatment option like Zepbound," Rhonda Pacheco, group vice president of Lilly Diabetes and Obesity, U.S., said in a company news rel

In a study comparing Eli Lilly's Mounjaro and Novo Nordisk's Ozempic, Mounjaro users lost significantly more weight. Over a year, 42.3% of Mounjaro users shed at least 15% body weight, compared to 19.3% with Ozempic. The study, yet to be peer-reviewed, involved over 18,000 patients and showed Mounjaro's superior weight loss effectiveness, with similar side effects to Ozempic.

A second injectable diabetes drug has been approved for weight loss in overweight and obese adults, the U.S. Food and Drug Administration announced Wednesday. The weight-loss drug Zepbound contains the same active ingredient, tirzepatide, as the diabetes drug Mounjaro.Zepbound works by activating hormone receptors in the body to reduce appetite

The U.S. Food and Drug Administration has received at least three reports of people being hospitalized after taking counterfeit versions of semaglutide.At least one of these reports includes mention of a counterfeit version of the Novo Nordisk medication Ozempic, CBS News reported. Ozempic and Wegovy, another semaglutide medication ma

Tirzepatide provides substantial additional reduction in body weight in participants who already achieved ≥5.0 percent weight reduction with an intensive lifestyle intervention, according to a study published online Oct. 15 in&nbsp;Nature Medicine&nbsp;to coincide with the annual meeting of The Obesity Society (ObesityWeek), held from Oct. 1

The annual meeting of the American College of Gastroenterology was held from Oct. 20 to 25 in Vancouver, British Columbia, Canada, and attracted participants from around the world, including gastroenterology and digestive disease specialists and other health care professionals. The conference featured presentations focusing on clinical updates in gastr

For patients with obesity seeing a general practitioner, presenting weight loss treatment as a positive opportunity is associated with increased uptake of treatment and more weight loss, according to a study published online Nov. 7 in the Annals of Internal Medicine.Charlotte Albury, D.Phil., from the University of Oxford in the United

A time-restricted eating (TRE) intervention without calorie counting is effective for weight loss and lowering hemoglobin A1c (HbA1c) levels among adults with obesity and type 2 diabetes, according to a study published online Oct. 27 in JAMA Network Open.Vasiliki Pavlou, R.D., from the University of Illinois Chicago, and colleagues exa